From a regulatory perspective, any death that occurs after an investigational product within 30 days is attributed to the article under investigation. For traditional vaccines, special adverse events of interest have a 24-month window of observation and potential concern. For genetic products (e.g., mRNA and adenoviral DNA), this window is extended to five years...